Analysis Note

Clotting activity is determined by comparison to a standard curve produced using normal pooled human plasma

General description

Native coagulation factor VIIa from human plasma prepared from human Factor VII using human Factor XIIa, which was removed after activation. In the coagulation process, after complexing with tissue factor and membrane phospholipids, Factor VIIa activates Factors IX and X to the enzymatically active Factors IXa and Xa. Provides a crossover point between the extrinsic and intrinsic pathways.

Native coagulation factor VIIa from human plasma prepared from human Factor VII using human Factor XIIa, which was removed after activation. Factor VIIa provides a crossover point between the extrinsic and intrinsic pathways. Prepared from human Factor VII using Human Factor XIIa.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Broze, G.J. 1994. In Haemostasis and Thrombosis, 3rd Edition(Bloom, et al. Eds.) Churchill Livingstone, Edinburgh, p 349.Majerus, P.W., et al. 1990. In The Pharmacological Basis of Therapeutics, 8th Edition (Gilman, A.G., et al. Eds.) Pergamon Press, New York, p 1311.

Packaging

10 µg in Plastic ampoule

Please refer to vial label for lot-specific concentration.

Physical form

In 100 mM NaCl, 20 mM Tris-HCl, pH 7.5.

Preparation Note

Prepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

Reconstitution

Following initial use aliquot and freeze (-70°C).

Warning

Toxicity: Standard Handling (A)